Trial Profile

A dose-escalation trial for ERAS-007 in combination with ERAS-601

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 09 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ERAS 007 (Primary) ; ERAS-601 (Primary)
Indications Acute myeloid leukaemia; Colorectal cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions
Sponsors Erasca

Most Recent Events

09 Sep 2022 New trial record
07 Sep 2022 According to an Erasca media release, the trial is expected to initiate in the first half of 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com